Integra: 3 Key Takeaways for Long-Term Investors

IART cut its full-year 2026 revenue guidance by $30 million after severe flooding at its Cincinnati plant and a slower-than-expected recovery in its tissue reconstruction business. The guidance reduction is the headline for near-term positioning.

Management says manufacturing capabilities are expected to resume in Q2 2027. That timeline puts the supply disruption well beyond the current fiscal year, which matters for anyone modeling revenue recovery.

The underlying numbers offer some offset. IART posted record operating cash flow of $96 million, and its neurosurgery segment grew 6.5% organically. Interpretation: the core franchise appears to be generating cash and growth even as one facility and one business line drag on the top line. That split is what the bull case rests on.

Management is prioritizing commercial execution and debt reduction. Strong cash generation supports the debt-paydown goal, which could help the balance sheet while production remains constrained. Whether that is enough to offset a guidance reset and a lengthy plant recovery is the open question for the stock.